Objectives: Infections caused by human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) represent a significant health problem. Co-infection with these viral agents is not uncommon as a result of the similar transmission routes. Our study was planned to investigate the prevalence of HBV and HCV infections in HIV/Acquired Immune Deficiency syndrome (AIDS) patients followed up at our institution. Materials and Methods: In this study conducted in the Department of Infectious Diseases and Clinical Microbiology at Izmir Tepecik Training and Research Hospital, medical records of patients followed at the HIV/AIDS outpatient clinic between August 2002 and December 2014 were evaluated. Demographic data, main route of HIV transmission, hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc) immunoglobulin G (IgG), anti-HBs and anti-HCV results were evaluated. Results: A total of 157 treatment-naïve patients who were followed up at our HIV/AIDS outpatient clinic were included in this study. Four patients (2.6%), had HBsAg positivity. Anti-HBc IgG and anti-HBs positivity were detected in 34% and 28.4% of the patients, respectively. No patients had anti-HCV positivity. Conclusion: The prevalence of HBsAg in HIV-positive individuals was found to be similar to that in other population-based studies in our country. Absence of anti-HCV positivity suggests that hepatitis C infection is not a major health problem in this population.
Introduction
Infections caused by human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) represent a significant health problem. Co-infection with these viral agents is not uncommon as a result of the similar of transmission routes. The main transmission routes of HBV infection among adults are sexual intercourse or intravenous (i.v.) drug use in low endemic countries, while horizontal and vertical transmission in high endemic countries (1) . Hepatitis C is mainly transmitted through contaminated blood, as is also the case with HIV (2) .
By the end of the year 2015, approximately 70 million people have been infected with HIV and 35 million deaths have occurred, with approximately 36.7 million people currently living with HIV (3). With respect to HBV, more than two billion people have been infected with this virus worldwide, and 350 to 400 million people are chronic carriers (4) . The number of individuals living with chronic HCV infection exceeds 130 million (5) . Among HIV-infected individuals, variable rates of HBV co-infection have been reported, ranging from 6% to 14% (6) , and approximately 20-30% of HIVpositive individuals are also infected with HCV (7) . The rates of HIV-HCV co-infection vary widely in different population groups depending on the geographical region, risk factors, age of infection, modes of transmission, and types of exposure (8) .
The introduction of highly active antiretroviral therapy (HAART) has significantly improved the survival in patients infected with HIV (9). However, liver disease caused by HBV and HCV co-infections, chronic alcohol abuse, hepatic tuberculosis or hepatotoxicity due to antiretroviral drugs have now emerged as a major cause of mortality in these patients (10, 11) . In co-infected patients, these viruses have significant interaction, amplifying the pathogenicity of individual agent, leading to higher morbidity and mortality (12, 13) . HIV infection is associated with an acceleration of the course of liver diseases caused by hepatitis B and C, particularly in patients with more pronounced immune deficiency. Thus, co-infected patients have more severe outcomes than monoinfected patients. From a clinical viewpoint, HIV-HBV co-infection is more severe and is associated with higher rates of cirrhosis and hepatocellular carcinoma. In such cases, the risk of cirrhosis increases 4.2-fold with an associated elevation in mortality, and, in some cases, HBV can be reactivated (14, 15, 16) . Several studies have shown that HIV-HCV co-infected patients are also at an increased risk of more rapid progression to cirrhosis, end-stage liver disease and hepatocellular carcinoma (8) . Therefore, an earlier recommendation by the World Health Organization involved the commencement of HAART in HIV patients co-infected with HBV or HCV (17) . This recommendation has recently been modified as to treat all patients irrespective of CD4 count. However, treatment in co-infected patients should be considered a priority, as a potential means to reduce liver-associated morbidity and mortality. Turkey is considered a low endemic country for HIV and HCV, and a low/intermediate endemic country (depending on the geographical region) for HBV infection. However, as opposed to the epidemiology of HBV and HCV, a recent rise in the number of HIV-infected individuals has been noted. On the other hand, there is a scarcity of studies examining this population in our country. Thus, this retrospective study was planned to investigate the prevalence of HBV and HCV infections in HIV/Acquired Immune Deficiency syndrome (AIDS) patients followed up at our institution.
Materials and Methods
In this study conducted at the Department of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, medical records of patients followed at the HIV/AIDS outpatient clinic between August 2002 and December 2014 were evaluated. Demographic data, potential route of HIV transmission, and hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc) immunoglobulin G (IgG), anti-HBs and anti-HCV results based on enzyme-linked immunosorbent assay (ELISA) (Diasorin Diagnostic Specialist S.T.A., Italy) at the time of presentation were recorded. The results were classified as positive or negative using the cut-off values provided by the manufacturer. Patients with missing data or incompliance to follow-up visits were excluded. Therefore, some of the statistical procedures did not involve the whole patient population enrolled.
Results
In this study, we included a total of 157 treatment-naive patients with anti-HIV positivity based on ELISA and confirmatory Western blot test who were followed up at our HIV/AIDS outpatient clinic. The mean age was 41 years (16-79 years), and 28 patients (18%) were female. Heterosexual intercourse was the most likely mode of transmission in 64.9%. Other potential routes of transmission were as follows in the decreasing order of frequency: bisexual/ homosexual intercourse, unknown, medical intervention/blood transfusion, and i.v. drug use ( Table 1 , 2). Four patients (2.6%), one of whom was a female, had HBsAg positivity. Anti-HBc IgG and anti-HBs positivity were detected in 34% and 28.4% of patients, respectively. No patients had anti-HCV positivity. Also, among 5554 subjects with HBV and 182 subjects with HCV followed up in our outpatient unit, none were anti-HIV-positive.
Discussion
According to the Turkish National Health Agency 2016 data, there were a total of 12.281 HIV-positive patients in Turkey, which is a low prevalence country. However, a recent and significant increase has occurred in the number of newly detected cases, with 1734 patients reported until December 2016 in the past year. Of these newly identified subjects, 84% were male and 16% were female; and 16.5% were non-nationals. Higher representation of young adults between 25 and 29 years of age was also noteworthy. There were only 529 new HIV-positive cases in 2010, and a more than 5-fold increase was found in 2015 reaching 2.130 new cases (18). Despite the regional variation in terms of HBV seroprevalence in Turkey, a trend toward a declined prevalence was observed probably due to the impact of routine nationwide childhood immunization program initiated in 1998. In a previous review, the reported rate of HBsAg seroprevalence in the general Turkish population was 2.5 to 9% (19) , which is comparable to the prevalence of HBV infection among HIV patients in our study, i.e. 2.6%. However, in another multi-center study from Turkey reported a higher rate of HBsAg positivity (6.2%) among HIV-positive individuals (20) . In the same study, 0.9% of subjects were anti-HCV positive. Similar results of HBsAg positivity (4.4%) was reported in a study conducted by İnci et al. (21) . In another study conducted with 70 (56 males, 14 females) HIV-infected patients, HBV and HCV co-infection rates were 14.2% and 12.8%, respectively while four (5.7%) patients were found to be infected with HBV, HCV and HIV (22) . Immunity against hepatitis B infection i.e. anti-HBs and anti-HBc IgG positivity was observed in 28.4%, isolated anti-HBc IgG positivity was observed in 1.9%, isolated anti-HBs positivity was observed in 9.03% of this population. This finding is consistent with the fact that the study participants were mostly middle-aged subjects who did not benefit from the routine vaccination program initiated in 1998. On the other hand, exposure to hepatitis B (anti-HBc IgG) was found in a greater proportion (34%) of these subjects. Overall, these data underscore the high level of HBV co-infection risk in HIV-positive subjects and underlie the importance of vaccination, particularly when one considers the recent findings showing a high representation of young adults among newly diagnosed patients with HIV positivity.
HCV infection is more likely occur in specific circumstances and specific patient groups with certain risks. In a study by Freitas et al. (23) , HIV-HCV co-infection was more likely to be associated with an age over 40 years, i.v. drug use, blood transfusion, and the absence of a steady partnership 8. The prevalence of HIV/HCV co-infection varies from one country to another depending on the route of HIV transmission: 10.8-42% in Brazil, 25% in the United States, 56.7% in Australia and 58.5% in Argentina.
Since i.v. drug use represents the main route of HCV transmission, HIV-HCV co-infection rates are higher among HIV/ AIDS patients with i.v. drug use. High HIV-HCV co-infection rates (approximately 70%) have been reported in Eastern European countries and in Iran where i.v. drug use is the main route of HIV transmission (20) . In a study of 378 HIV-positive individuals in Kenya, 1% was found to be co-infected with HCV (24) . Again, in a cohort of 138 HIV-positive patients in Ghana, HCV co-infection was found in 3.6% (25) . In a meta-analysis of studies reporting HCV prevalence amongst HIV patients in sub-Saharan Africa, the mean prevalence of co-infection was 7% (26) . According to 2008-2012 data from the Turkish Red Crescent Blood Center, anti-HCV was found to be positive in 0.02 to 0.004% of a total of civilian donor population of 4.510.207 (27, 28) . The study conducted by the Turkish Association for the Study of the Liver between 2008 and 2011 found that 0.95% of 5.471 subjects were positive for HCV (29) . The prevalence of anti-HCV positivity in the general Turkish population has been reported to be 1-2.2% (30) . A number of factors, including anal sex, multiple partners, and co-infection with HIV and other sexually transmitted diseases, have been implicated in the increase in HCV seroconversion among HIVpositive men who have sex with men (MSM) (31, 32) . In this study, no anti-HCV positivity was found in this population of patients infected with HIV, possibly related to the difference in transmission routes of HIV among patients included in this study. Accordingly, heterosexual intercourse was reported to be the main route of transmission, and relatively low numbers of patients were MSM/ bisexual (24.2%) and i.v. drug users (1.3%). In a previous study conducted in Turkey, the prevalence of i.v. drug use was 0.05% in the general population (33) . Although heterosexual intercourse was reported to be the main route of HIV transmission, the significantly higher proportion of male participants suggests that the actual number of individuals experiencing same-sex intercourse may be higher. On the other hand, individuals may opt to conceal their sexual preferences due to a number of factors such as fear of stigmatization or disclosure. Thus, absence of anti-HCV-positive patients in our sample is most likely due to the low number of i.v. drug users and low HCV prevalence nationwide. All HIV-infected patients should be tested for HCV infection. False negative anti-HCV results may be seen in HIV-positive individuals with low CD4 (<100/mm 3 ) counts. If anti-HCV is negative and HCV infection is still suspected, HCV RNA should be performed (5) .
Study Limitations
Certain limitations of our study should be mentioned. It was a single-center study from western Turkey with a small sample size, restricting its ability to reflect the current status in the country.
Conclusion
As a conclusion, it confirms the previous national data indicating a high prevalence of HBsAg among HIV-positive individuals and emphasizing the requirement for effective immunization in susceptible populations. Absence of anti-HCV positivity suggests that HCV infection may not represent a major health problem in our population.
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